Biote Corp. BTMD Unsatisfied Pellet Procedures — Deferred Revenue

Similar metrics at other companies

FDMTDeferred Revenue — Deferred Revenue

$2.49M—

OOMAProduct — Deferred Revenue

$80K+1,233%

SIGOther Deferred Revenue — Contract with Customer, Liability

$86.5M+6.9%

NUVBProduct Revenue — Deferred Revenue

$100K—

STXSProduct Shipped Revenue Deferred — Deferred Revenue

$781K-56.4%

CAKEPromotional Programs — Deferred Revenue

$26.8M-14.4%

Questions, answered.

What is Biote Corp.'s unsatisfied pellet procedures — deferred revenue?

Biote Corp. (BTMD) reported unsatisfied pellet procedures — deferred revenue of $1.62M in Q1 2026.

How has Biote Corp.'s unsatisfied pellet procedures — deferred revenue changed year-over-year?

Biote Corp.'s unsatisfied pellet procedures — deferred revenue decreased by 9.9% year-over-year, from $1.79M to $1.62M.

What is the long-term trend for Biote Corp.'s unsatisfied pellet procedures — deferred revenue?

Over 2 years (2023 to 2025), Biote Corp.'s unsatisfied pellet procedures — deferred revenue has grown at a 19.0% compound annual growth rate (CAGR), from $5.02M to $7.12M.

What does unsatisfied pellet procedures — deferred revenue mean?

This metric represents the total aggregate deferred revenue liability for hormone pellet procedures that have been invoiced or paid but remain unfulfilled. It acts as a comprehensive measure of the company's total outstanding performance obligations to its certified practitioners and their patients. Tracking this total liability provides insight into the overall scale of the company's service backlog and the potential revenue pipeline waiting to be recognized.